Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o

Item

http://www.wikidata.org/entity/Q34388837

Q34388837

about

Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review Hemostatic management of patients undergoing ear-nose-throat surgery Periprocedural Management of Non-Vitamin K Oral Anticoagulants in Chronic Kidney Disease: A Review of Existing Heterogeneity and Contemporary Evidence Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review Anticoagulation in atrial fibrillation Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Perioperative management of patients on direct oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications.Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).The Impact of Uninterrupted Warfarin on Hand and Wrist Surgery.Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.Using new oral anticoagulants in patients undergoing major orthopedic surgery.Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.Discontinuation of oral anticoagulation preceding acute ischemic stroke--prevalence and outcomes: Comprehensive chart review.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.Safety of Anticoagulation Interruption in Patients Undergoing Surgery or Invasive Procedures: A Systematic Review and Meta-analyses of Randomized Controlled Trials and Non-randomized Studies.Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery.Anticoagulation Bridge Therapy in Patients with Atrial Fibrillation: Recent Updates Providing a Rebalance of Risk and Benefit.Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey.Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation.Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice.Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.Direct Oral Anticoagulants: An Overview for the Interventional Radiologist.Perioperative management of new oral anticoagulants in patients undergoing elective surgery at a tertiary hospital.Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.Management of oral antiplatelet agents and anticoagulation therapy before bronchoscopy.

P2860

Q26765949-4D4051AF-F24B-4F96-9568-B4EA857A069C Q26771864-9734678A-7FAB-446A-BF27-90ACE1A45E15 Q28071393-35B36ABF-E062-4B10-9155-A7F121ECEFB4 Q28076077-8BF3BB20-6779-4BFA-881D-DF6211B86135 Q28078177-D1DE1EFE-5B78-4B7D-A6CD-DB66DB0FBEE0 Q28315636-896393FC-B546-4300-9AAB-6E50233BBDF3 Q30000079-39BCCC9D-EA01-4401-9F37-FED22136E2C0 Q30653045-220ED341-D552-45AE-A843-9BB3D44140AC Q30994474-D5B73A26-FBF0-4193-8155-D08B9F7ACC2F Q33692054-CB5F8D0A-6ED0-4286-8CA9-F34E088C541B Q34207558-D35A69EE-DEE4-48A0-9EED-56A901694757 Q34511297-17C55774-6B58-4B42-BAE8-B75234C841C6 Q34670808-425A5554-7EFC-474F-82AF-A99368FC631E Q34683960-5F9A4155-5410-4A5B-AE15-CD448AF84E96 Q34688742-F411D670-ECE1-4822-B9DC-4B22D0937C56 Q35044476-EEA03866-9583-4525-8227-D23D04E106A8 Q36485362-37D24CEB-AE03-43B8-8A25-0D7645574A44 Q36714127-ABEC29D2-C1F0-4618-A14A-C4A04FBA1BBB Q37062044-8C47D0B5-7653-4388-B380-3BA171B1E4B8 Q37176172-FC213B43-A12E-408B-9B7F-D5985884022F Q38375586-76AC2F3A-F0DC-4E74-A7B2-D9F1E8D8771F Q38411840-318786D4-097F-4DD3-937B-3D3DDA1803C9 Q38524254-D70F7C33-D7AE-4FF4-BDC9-972F0C51C943 Q38560334-FD3B453B-5A3F-4CCD-99F6-BA2F0BB5996A Q38647787-392DA789-67FB-49F8-B114-5DF0BE2638C4 Q38655829-20C70D42-1DCC-4A25-B2E8-7874DCCFEF26 Q38655951-CE2966C0-812C-4729-9DB9-F959F0C40541 Q38694936-3512C2BF-0AD2-4AE7-B38B-DC217234C9E0 Q38728496-580C79A8-ECCF-4C56-B2A0-621ED415CB7B Q38779161-3DC55CE9-DA75-4100-94A2-19402B22B778 Q38802398-87F3833A-C31A-4922-80F4-1A3F5CEA83CC Q38902986-F3B0CBBF-1EED-42A8-9986-4DC05EF58BF1 Q38935753-9250D1B1-2451-41FD-92A3-06946D55E5CF Q38939246-CBAFE853-BE98-4412-9493-62100D3A3603 Q38953655-ED8C9B48-B7C6-4D98-8CB7-30C34313C757 Q38975409-96630BA9-0AF1-4398-BE5E-E1898C56A2FD Q39028122-B1AA09E5-8873-4B89-9097-5E31DF899526 Q40169685-D6CC41B6-EFF2-4DDE-948B-8E031EEF092E Q40478828-70537BC7-B874-4CA4-A3A3-77E771BD6FA5 Q47110229-EF89F550-D648-479E-B792-7D24F08F91F1

P2860

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o

Item

http://www.wikidata.org/entity/Q34388837

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu